Elosua-González Marta, Pampín-Franco Ana, Mazzucchelli-Esteban Ramón, Mielgo-Rubio Xabier, Rodriguez-Vásquez Ximena, García-Zamora Elena, López-Estebaranz Jose Luis
Department of Dermatology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
Dermatol Online J. 2017 Aug 15;23(8):13030/qt12n4m6pm.
Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxicities and skin toxicities. Herein, we report a case of predominantly palmoplantar psoriasis with severe nail involvement, psoriatic arthritis, and autoimmune hypothyroidism after receiving nivolumab treatment for lung cancer. We also summarize the case reports that have been published previously. The knowledge of these irAEs in patients undergoing anti-PD1 therapy is important since it will enable earlier recognition and appropriate management, with the aim of maintaining effective dose without disruption.
纳武单抗是一种针对程序性细胞死亡蛋白1（PD-1）的单克隆抗体，在包括黑色素瘤、肺癌和肾癌在内的晚期恶性肿瘤患者中已显示出有前景的结果。免疫相关不良事件（irAEs）已有报道，包括器官特异性毒性和皮肤毒性。在此，我们报告1例在接受纳武单抗治疗肺癌后出现以掌跖部银屑病为主且伴有严重甲受累、银屑病关节炎和自身免疫性甲状腺功能减退的病例。我们还总结了先前已发表的病例报告。了解接受抗PD-1治疗患者的这些irAEs很重要，因为这将有助于早期识别和恰当处理，目的是在不中断治疗的情况下维持有效剂量。
